A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

被引：38

作者：

Zeidan, Amer M. ^{[1
,2
]}

DeAngelo, Daniel J. ^{[3
]}

Palmer, Jeanne M. ^{[4
]}

Seet, Christopher S. ^{[5
]}

Tallman, Martin S. ^{[6
]}

Wei, Xin ^{[7
]}

Li, Ying Fei ^{[8
]}

Hock, Nanette ^{[9
]}

Burgess, Michael R. ^{[9
]}

Hege, Kristen ^{[9
]}

Stock, Wendy ^{[10
]}

机构：

[1] Yale Univ, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Mayo Clin, Phoenix, AZ USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Celgene Corp, Berkeley, NJ USA

[8] Celgene Corp, Summit, NJ USA

[9] Celgene Corp, San Francisco, CA USA

[10] Univ Chicago Med, Chicago, IL USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-125363

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1320

引用

页数：6

共 50 条

[41] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Kadia, Tapan
Ning, Jing
Gonzalez, Graciela Nogueras
Pierce, Sherry
Kelly, Mary
Zhang, Weiguo
Gombos, Dan
Kornblau, Steven
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Andreeff, Michael
BLOOD, 2017, 130
[42] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Ravandi, Farhad
Garcia-Manero, Guillermo
Jabbour, Elias
DiNardo, Courtney D.
Kadia, Tapan M.
Ning, Jing
Nogueras-Gonzalez, Graciela
Pierce, Sherry
Gombos, Dan
Komblau, Steven
Konopleva, Marina
Kelly, Mary
Borthakur, Gautam
Zhang, Weiguo
Cortes, Jorge
Kantarjian, Hagop
Andreeffl, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
[43] A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Bachier, Carlos
Borthakur, Gautam
Hosing, Chitra
Blum, William
Rotta, Marcello
Ojeras, Paulius
Barnett, Brian
Rajangam, Kanya
Majhail, Navneet S.
Nikiforow, Sarah
BLOOD, 2020, 136
[44] Phase I study of Triapine® and cytarabine (ara-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS).
Yee, KWL
Cortes, J
Garcia-Manero, G
Verstovsek, S
Ferrajoli, A
Wierda, WG
Thomas, D
Faderl, S
King, I
O'Brien, SM
Sznol, M
Giles, FJ
BLOOD, 2005, 106 (11) : 311B - 311B
[45] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
Swaminathan, Mahesh
Dinardo, Courtney Denton
Maiti, Abhishek
Pemmaraju, Naveen
Ohanian, Maro
Daver, Naval Guastad
Garcia-Manero, Guillermo
Issa, Ghayas C.
Borthakur, Gautam
Ravandi-Kashani, Farhad
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Valero, Yesid Alvarado
Jabbour, Elias
Short, Nicholas James
Wierda, William G.
Jain, Nitin
Kornblau, Steven Mitchell
Kantarjian, Hagop M.
Konopleva, Marina
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
Stein, Eytan M.
Dinardo, Courtney Denton
Pollyea, Daniel Aaron
Fathi, Amir Tahmasb
Roboz, Gail J.
Altman, Jessica K.
Stone, Richard M.
Flinn, Ian
Kantarjian, Hagop M.
Collins, Robert
Patel, Manish R.
Stein, Anthony Selwyn
Sekeres, Mikkael A.
Swords, Ronan T.
Medeiros, Bruno C.
Knight, Robert D.
Agresta, Samuel V.
De Botton, Stephane
Tallman, Martin S.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[47] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
Assi, Rita
Kantarjian, Hagop M.
Daver, Naval G.
Garcia-Manero, Guillermo
Benton, Christopher B.
Thompson, Philip A.
Borthakur, Gautam
Kadia, Tapan M.
Alvarado, Yesid
Jabbour, Elias J.
Konopleva, Marina Y.
Takahashi, Koichi
Kornblau, Steven M.
DiNardo, Courtney D.
Estrov, Zeev E.
Flores, Wilmer
Basu, Sreyashi
Allison, James P.
Sharma, Padmanee
Pierce, Sherry A.
Pike, Allison
Cortes, Jorge E.
Ravandi, Farhad
BLOOD, 2018, 132
[48] Odyssey: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor Abd-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Benajiba, Lina
Colle, Julien
Heiblig, Mael
Loron, Sandrine
Soret-Dulphy, Juliette
Berchard, Paul
Yazir, Muhube
Basset, Laurent
Venton, Geoffroy
Larcher, Marie-Virginie
De Oliveira, Rafael Daltro
Fossard, Gaelle
Martin, Guillaume
Perez, Mileidys
Ceylan, Ismael
Pelletier, Annick
Kiladjian, Jean-Jacques
Costello, Regis
BLOOD, 2024, 144 : 6001 - 6002
[49] Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
Senapati, Jayastu
Almanza, Emmanuel Huante
Kadia, Tapan M.
Montalban-Bravo, Guillermo
Faderl, Stefan
Sasaki, Koji
Short, Nicholas
Daver, Naval
DiNardo, Courtney D.
Masarova, Lucia
Ferrajoli, Alessandra
Jabbour, Elias
Borthakur, Gautam
Al Azzawi, Hind
Konopleva, Marina
Garcia-Manero, Guillermo
Andreeff, Michael
Kantarjian, Hagop
Ravandi, Farhad
Alvarado, Yesid
BLOOD, 2022, 140 : 9050 - 9053
[50] A Phase II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed Acute Myeloid Leukemia (AML)
Kim, Kunhwa
Kantarjian, Hagop
Borthakur, Gautam
Takahashi, Koichi
Short, Nicholas J.
DiNardo, Courtney D.
Jabbour, Elias J.
Chien, Kelly S.
Daver, Naval
Pemmaraju, Naveen
Jain, Nitin
Adewale, Lade
Montalban-Bravo, Guillermo
Wierda, William G.
Verstovsek, Srdan
Konopleva, Marina
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2021, 138

← 1 2 3 4 5 →